Leerink Partnrs Forecasts Reduced Earnings for Climb Bio

Climb Bio, Inc. (NASDAQ:CLYM) – Equities researchers at Leerink Partnrs reduced their FY2025 EPS estimates for Climb Bio in a research note issued on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now anticipates that the company will earn ($0.66) per share for the year, down from their previous forecast of ($0.65). Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Climb Bio’s current full-year earnings is ($1.57) per share. Leerink Partnrs also issued estimates for Climb Bio’s FY2026 earnings at ($0.83) EPS, FY2027 earnings at ($1.14) EPS and FY2028 earnings at ($1.77) EPS.

Climb Bio (NASDAQ:CLYM) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.13) EPS for the quarter.

Separately, Leerink Partners began coverage on Climb Bio in a research note on Monday, December 2nd. They issued an “outperform” rating and a $10.00 price objective for the company.

Climb Bio Stock Down 6.0 %

Shares of CLYM opened at $1.58 on Monday. The firm’s 50 day simple moving average is $2.14. The stock has a market capitalization of $106.21 million, a P/E ratio of -0.74 and a beta of -0.24. Climb Bio has a 12 month low of $1.55 and a 12 month high of $11.55.

About Climb Bio

Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.